307 related articles for article (PubMed ID: 35219377)
1. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
Craig T; Magerl M; Levy DS; Reshef A; Lumry WR; Martinez-Saguer I; Jacobs JS; Yang WH; Ritchie B; Aygören-Pürsün E; Keith PK; Busse P; Feuersenger H; Pawaskar D; Jacobs I; Pragst I; Doyle MK
Lancet; 2022 Mar; 399(10328):945-955. PubMed ID: 35219377
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Craig TJ; Reshef A; Li HH; Jacobs JS; Bernstein JA; Farkas H; Yang WH; Stroes ESG; Ohsawa I; Tachdjian R; Manning ME; Lumry WR; Saguer IM; Aygören-Pürsün E; Ritchie B; Sussman GL; Anderson J; Kawahata K; Suzuki Y; Staubach P; Treudler R; Feuersenger H; Glassman F; Jacobs I; Magerl M
Lancet; 2023 Apr; 401(10382):1079-1090. PubMed ID: 36868261
[TBL] [Abstract][Full Text] [Related]
3. Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.
Craig TJ; Levy DS; Reshef A; Lumry WR; Martinez-Saguer I; Jacobs JS; Yang WH; Ritchie B; Aygören-Pürsün E; Keith PK; Busse P; Feuersenger H; Alexandru Bica M; Jacobs I; Pragst I; Magerl M
Lancet Haematol; 2024 Jun; 11(6):e436-e447. PubMed ID: 38710185
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial.
Riedl MA; Grivcheva-Panovska V; Moldovan D; Baker J; Yang WH; Giannetti BM; Reshef A; Andrejevic S; Lockey RF; Hakl R; Kivity S; Harper JR; Relan A; Cicardi M
Lancet; 2017 Sep; 390(10102):1595-1602. PubMed ID: 28754491
[TBL] [Abstract][Full Text] [Related]
5. Interventions for the long-term prevention of hereditary angioedema attacks.
Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
Fukuda T; Yamagami K; Kawahata K; Suzuki Y; Sasaki Y; Miyagi T; Jacobs I; Lawo JP; Glassman F; Akama H; Hide M; Ohsawa I
Allergol Int; 2023 Jul; 72(3):451-457. PubMed ID: 36858856
[TBL] [Abstract][Full Text] [Related]
7. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.
Craig TJ; Bewtra AK; Hurewitz D; Levy R; Janss G; Jacobson KW; Packer F; Bernstein JA; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
Allergy Asthma Proc; 2012; 33(4):354-61. PubMed ID: 22856636
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hereditary angioedema-single or multiple pathways to the rescue.
Valerieva A; Longhurst HJ
Front Allergy; 2022; 3():952233. PubMed ID: 36172291
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.
Riedl M
Clin Drug Investig; 2015 Jul; 35(7):407-17. PubMed ID: 26091744
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.
Craig T; Zuraw B; Longhurst H; Cicardi M; Bork K; Grattan C; Katelaris C; Sussman G; Keith PK; Yang W; Hébert J; Hanzlikova J; Staubach-Renz P; Martinez-Saguer I; Magerl M; Aygören-Pürsün E; Farkas H; Reshef A; Kivity S; Neri S; Crisan I; Caballero T; Baeza ML; Hernandez MD; Li H; Lumry W; Bernstein JA; Hussain I; Anderson J; Schwartz LB; Jacobs J; Manning M; Levy D; Riedl M; Christiansen S; Feuersenger H; Pragst I; Mycroft S; Pawaskar D; Jacobs I;
J Allergy Clin Immunol Pract; 2019; 7(6):1793-1802.e2. PubMed ID: 30772477
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema.
Riedl MA; Lumry WR; Li HH; Banerji A; Bernstein JA; Ba M; Bjrkander J; Magerl M; Maurer M; Rockich K; Chen H; Schranz J
Allergy Asthma Proc; 2016 Nov; 37(6):489-500. PubMed ID: 27931305
[TBL] [Abstract][Full Text] [Related]
12. An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
Aygören-Pürsün E; Zanichelli A; Cohn DM; Cancian M; Hakl R; Kinaciyan T; Magerl M; Martinez-Saguer I; Stobiecki M; Farkas H; Kiani-Alikhan S; Grivcheva-Panovska V; Bernstein JA; Li HH; Longhurst HJ; Audhya PK; Smith MD; Yea CM; Maetzel A; Lee DK; Feener EP; Gower R; Lumry WR; Banerji A; Riedl MA; Maurer M
Lancet; 2023 Feb; 401(10375):458-469. PubMed ID: 36774155
[TBL] [Abstract][Full Text] [Related]
13. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.
Longhurst H; Cicardi M; Craig T; Bork K; Grattan C; Baker J; Li HH; Reshef A; Bonner J; Bernstein JA; Anderson J; Lumry WR; Farkas H; Katelaris CH; Sussman GL; Jacobs J; Riedl M; Manning ME; Hebert J; Keith PK; Kivity S; Neri S; Levy DS; Baeza ML; Nathan R; Schwartz LB; Caballero T; Yang W; Crisan I; Hernandez MD; Hussain I; Tarzi M; Ritchie B; Králíčková P; Guilarte M; Rehman SM; Banerji A; Gower RG; Bensen-Kennedy D; Edelman J; Feuersenger H; Lawo JP; Machnig T; Pawaskar D; Pragst I; Zuraw BL;
N Engl J Med; 2017 Mar; 376(12):1131-1140. PubMed ID: 28328347
[TBL] [Abstract][Full Text] [Related]
14. Preventing Hereditary Angioedema Attacks in Children Using Cinryze®: Interim Efficacy and Safety Phase 3 Findings.
Aygören-Pürsün E; Soteres D; Moldovan D; Christensen J; Van Leerberghe A; Hao J; Schranz J; Jacobson KW; Martinez-Saguer I
Int Arch Allergy Immunol; 2017; 173(2):114-119. PubMed ID: 28662509
[TBL] [Abstract][Full Text] [Related]
15. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
[TBL] [Abstract][Full Text] [Related]
16. A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab.
McKenzie A; Roberts A; Malandkar S; Feuersenger H; Panousis C; Pawaskar D
Clin Transl Sci; 2022 Mar; 15(3):626-637. PubMed ID: 34859955
[TBL] [Abstract][Full Text] [Related]
17. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks--final results of the I.M.P.A.C.T.2 study.
Craig TJ; Bewtra AK; Bahna SL; Hurewitz D; Schneider LC; Levy RJ; Moy JN; Offenberger J; Jacobson KW; Yang WH; Eidelman F; Janss G; Packer FR; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
Allergy; 2011 Dec; 66(12):1604-11. PubMed ID: 21884533
[TBL] [Abstract][Full Text] [Related]
18. Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert
Bouillet L; Boccon-Gibod I; Gompel A; Floccard B; Martin L; Blanchard-Delaunay C; Launay D; Fain O
Eur J Dermatol; 2017 Apr; 27(2):155-159. PubMed ID: 28251901
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Hereditary Angioedema.
Caballero T
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):1-16. PubMed ID: 33602658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
